A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Trial details
- Registry ID
- NCT07065240
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Glyph Allopregnanolone; GlyphAllo; LYT-300
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)NCT07065240 | Seaport Therapeutics | Phase 2 | Recruiting | 2027-03Estimated |
| An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)NCT07161700 | Seaport Therapeutics | Phase 2 | Enrolling by invitation | 2027-05Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |